PY1908892A - Composiciones anticonceptivas con efectos cardiovasculaes reducidos - Google Patents
Composiciones anticonceptivas con efectos cardiovasculaes reducidosInfo
- Publication number
- PY1908892A PY1908892A PY201901908892A PY1908892A PY1908892A PY 1908892 A PY1908892 A PY 1908892A PY 201901908892 A PY201901908892 A PY 201901908892A PY 1908892 A PY1908892 A PY 1908892A PY 1908892 A PY1908892 A PY 1908892A
- Authority
- PY
- Paraguay
- Prior art keywords
- thromboembolism
- cardiovascular effects
- reduced cardiovascular
- contraceptive compositions
- reduced
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
La presente invención se refiere a un método anticonceptivo con efectos cardiovasculares reducidos, tal como riesgo reducido de tromboembolismo, tal como riesgo reducido de tromboembolismo venoso (TEV) y riesgo reducido de tromboembolismo aórtico (TEA). El método de la invención comprende adminsitrar a un mamífero hembra una cantidad de un componente estetrol en combinación con un componente progestagénico. El método tiene un perfil favorable para el tromboembolismo en comparación con los métodos actualmente disponibles que emplean anticonceptivos de la llamada segunda, tercera o cuarta generación.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18155571 | 2018-02-07 | ||
| EP18160586 | 2018-03-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PY1908892A true PY1908892A (es) | 2019-10-15 |
Family
ID=65278388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PY201901908892A PY1908892A (es) | 2018-02-07 | 2019-02-07 | Composiciones anticonceptivas con efectos cardiovasculaes reducidos |
Country Status (20)
| Country | Link |
|---|---|
| EP (2) | EP4140489A1 (es) |
| JP (2) | JP2021513507A (es) |
| KR (1) | KR102717921B1 (es) |
| CN (2) | CN115429806A (es) |
| AU (1) | AU2019219070B2 (es) |
| CA (2) | CA3178181A1 (es) |
| CL (1) | CL2020002017A1 (es) |
| EC (1) | ECSP20054822A (es) |
| GE (2) | GEAP202215414A (es) |
| IL (1) | IL276584B2 (es) |
| JO (1) | JOP20200169A1 (es) |
| MA (1) | MA51733A (es) |
| NZ (1) | NZ766027A (es) |
| PH (1) | PH12020500601A1 (es) |
| PY (1) | PY1908892A (es) |
| SG (1) | SG11202007163WA (es) |
| TW (1) | TWI845496B (es) |
| UA (1) | UA126746C2 (es) |
| UY (1) | UY38075A (es) |
| WO (1) | WO2019154899A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3701944T3 (da) | 2015-06-18 | 2022-03-14 | Estetra Srl | Oro-dispergerbar doseringsenhed indeholdende en estetrolkomponent |
| LT3310346T (lt) | 2015-06-18 | 2021-06-10 | Estetra Sprl | Burnoje disperguojama tabletė, turinti estetrolio |
| LT3310345T (lt) | 2015-06-18 | 2021-06-25 | Estetra Sprl | Burnoje disperguojama tabletė, turinti estetrolio |
| CR20180042A (es) | 2015-06-18 | 2018-05-03 | Mithra Pharmaceuticals S A | Unidad de dosificación orodispersable que contiene un componente estetrol. |
| KR102712911B1 (ko) | 2016-08-05 | 2024-10-04 | 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 | 월경통 및 생리통의 관리방법 |
| CN111989105B (zh) | 2018-04-19 | 2024-07-19 | 埃斯特拉私人有限责任公司 | 化合物以及它们在缓解绝经相关症状中的用途 |
| TWI801561B (zh) | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
| HU231240B1 (hu) | 2019-09-03 | 2022-04-28 | Richter Gedeon Nyrt. | Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására |
| TWI893101B (zh) * | 2020-04-16 | 2025-08-11 | 比利時商埃斯特拉有限責任公司 | 具有降低之副作用之避孕組成物 |
| WO2022248733A1 (en) | 2021-05-28 | 2022-12-01 | Neuralis Sa | Use of estetrol in treatment of respiratory infection diseases |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4344405C2 (de) | 1993-12-24 | 1995-12-07 | Marika Dr Med Ehrlich | Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption |
| EP1390042B1 (en) * | 2001-05-23 | 2007-11-28 | Pantarhei Bioscience B.V. | Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception |
| EP1535618A1 (en) * | 2003-11-26 | 2005-06-01 | Schering Aktiengesellschaft | Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions |
| CA2762640A1 (en) * | 2009-05-22 | 2010-11-25 | Stefanie Lindemann | Medication for oral administration, comprising at least one estrogen and/or at least one gestagen and at least one probiotic bacterial strain |
| WO2012055840A1 (en) * | 2010-10-28 | 2012-05-03 | Bayer Pharma Aktiengesellschaft | Composition and preparation for treatment of dysmenorrhea and menstrual pain and use of a hormonal agent and a zinc salt for treatment of menstrual disorders |
| JP6447931B2 (ja) * | 2013-12-12 | 2019-01-09 | ドネスタ バイオサイエンス ビー．ブイ．Ｄｏｎｅｓｔａ Ｂｉｏｓｃｉｅｎｃｅ Ｂ．Ｖ． | エステトロール成分を含有する口腔内崩壊固体単位剤形 |
| CA3041016C (en) | 2016-10-28 | 2023-09-05 | Estetra Sprl | Method for the management of dysmenorrhea and menstrual pain |
| KR102712911B1 (ko) * | 2016-08-05 | 2024-10-04 | 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 | 월경통 및 생리통의 관리방법 |
-
2019
- 2019-02-07 SG SG11202007163WA patent/SG11202007163WA/en unknown
- 2019-02-07 IL IL276584A patent/IL276584B2/en unknown
- 2019-02-07 CN CN202211257175.1A patent/CN115429806A/zh active Pending
- 2019-02-07 PY PY201901908892A patent/PY1908892A/es unknown
- 2019-02-07 AU AU2019219070A patent/AU2019219070B2/en active Active
- 2019-02-07 GE GEAP202215414A patent/GEAP202215414A/en unknown
- 2019-02-07 WO PCT/EP2019/052980 patent/WO2019154899A1/en not_active Ceased
- 2019-02-07 GE GEAP201915414A patent/GEP20227407B/en unknown
- 2019-02-07 CA CA3178181A patent/CA3178181A1/en active Pending
- 2019-02-07 EP EP22199066.6A patent/EP4140489A1/en active Pending
- 2019-02-07 JP JP2020538823A patent/JP2021513507A/ja active Pending
- 2019-02-07 UA UAA202005421A patent/UA126746C2/uk unknown
- 2019-02-07 NZ NZ766027A patent/NZ766027A/en unknown
- 2019-02-07 JO JOP/2020/0169A patent/JOP20200169A1/ar unknown
- 2019-02-07 UY UY38075A patent/UY38075A/es not_active Application Discontinuation
- 2019-02-07 KR KR1020207025456A patent/KR102717921B1/ko active Active
- 2019-02-07 CA CA3089804A patent/CA3089804A1/en active Pending
- 2019-02-07 EP EP19703103.2A patent/EP3749327A1/en active Pending
- 2019-02-07 MA MA051733A patent/MA51733A/fr unknown
- 2019-02-07 CN CN201980012248.0A patent/CN111683664A/zh active Pending
- 2019-02-11 TW TW108104465A patent/TWI845496B/zh active
-
2020
- 2020-07-13 PH PH12020500601A patent/PH12020500601A1/en unknown
- 2020-07-31 CL CL2020002017A patent/CL2020002017A1/es unknown
- 2020-09-04 EC ECSENADI202054822A patent/ECSP20054822A/es unknown
-
2023
- 2023-09-28 JP JP2023168039A patent/JP7651645B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024009834A (ja) | 2024-01-23 |
| CN111683664A (zh) | 2020-09-18 |
| JOP20200169A1 (ar) | 2020-07-07 |
| IL276584B2 (en) | 2024-10-01 |
| CA3178181A1 (en) | 2019-08-15 |
| IL276584B1 (en) | 2024-06-01 |
| EP3749327A1 (en) | 2020-12-16 |
| AU2019219070B2 (en) | 2024-12-19 |
| TW202011967A (zh) | 2020-04-01 |
| SG11202007163WA (en) | 2020-08-28 |
| GEAP202215414A (en) | 2022-04-25 |
| ECSP20054822A (es) | 2020-12-31 |
| AU2019219070A1 (en) | 2020-09-24 |
| IL276584A (en) | 2020-09-30 |
| JP7651645B2 (ja) | 2025-03-26 |
| NZ766027A (en) | 2026-03-27 |
| GEP20227407B (en) | 2022-08-25 |
| PH12020500601A1 (en) | 2021-05-17 |
| CN115429806A (zh) | 2022-12-06 |
| WO2019154899A1 (en) | 2019-08-15 |
| KR20200118464A (ko) | 2020-10-15 |
| CA3089804A1 (en) | 2019-08-15 |
| UY38075A (es) | 2019-10-01 |
| MA51733A (fr) | 2020-12-16 |
| CL2020002017A1 (es) | 2020-12-04 |
| EP4140489A1 (en) | 2023-03-01 |
| TWI845496B (zh) | 2024-06-21 |
| JP2021513507A (ja) | 2021-05-27 |
| UA126746C2 (uk) | 2023-01-18 |
| KR102717921B1 (ko) | 2024-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PY1908892A (es) | Composiciones anticonceptivas con efectos cardiovasculaes reducidos | |
| MX2018011348A (es) | Composiciones de extractos naturales y uso de los mismos para prevenir o tratar enfermedades. | |
| MX2018008010A (es) | Composicion y metodo para el crecimiento del pelo. | |
| MX2019007586A (es) | Composiciones que comprenden tacrolimus para el tratamiento de enfermedades inflamatorias intraoculares. | |
| DOP2018000297A (es) | Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo | |
| CL2019000107A1 (es) | Composiciones de arni contra el componente c5 del complemento y métodos para su uso.(divisional solicitud 201702014) | |
| MX2018005745A (es) | Control de niveles redox celulares. | |
| CL2017002636A1 (es) | Composiciones que comprenden una combinación de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo. | |
| MX2021005801A (es) | Metodos para administrar corticosteroides. | |
| CL2020002252A1 (es) | Formulación oftálmica. | |
| NI201800139A (es) | Formulación farmacéutica líquida estable | |
| CO2019001044A2 (es) | Composición de cannabis | |
| MX2019001298A (es) | Metodo de manejo de dismenorrea y dolor menstrual. | |
| BR112017025859A2 (pt) | colocação de shunt intraocular ab externo | |
| MX2017003037A (es) | Esteroides neuroactivos, composiciones y usos de los mismos. | |
| AR101455A1 (es) | Molécula portadora | |
| MX2020013120A (es) | Tratamiento terapéutico de cánceres de microsatélites inestables. | |
| CO2017011046A2 (es) | Prenda absorbente con buen ajuste | |
| BR112019004560A2 (pt) | tratamento combinado com agonista de tlr7 e um inibidor de formação de capsídeo de hbv | |
| PE20151947A1 (es) | Reduccion de la respuesta proinflamatoria | |
| CL2022001021A1 (es) | Una forma de dosificación parenteral estable de acetato de cetrorelix | |
| CO2020005366A2 (es) | Composición plaguicida que contiene tidiazurón y ácido poliglutámico | |
| BR112017010933A2 (pt) | composição farmacêutica | |
| MX385405B (es) | Composición inyectable en el vítreo de un ojo que comprende un inhibidor de cinasa y el uso de la misma para tratar una enfermedad ocular. | |
| AR112448A1 (es) | Derivados de xantina sustituidos |